What are the indications, dosing regimen, and contraindications for Paxlovid (nirmatrelvir/ritonavir) in non‑hospitalized adults and adolescents with COVID‑19?

Paxlovid (Nirmatrelvir/Ritonavir) for COVID-19

Paxlovid should be prescribed for non-hospitalized adults with mild-to-moderate COVID-19 who are at high or moderate risk for progression to severe disease, initiated within 5 days of symptom onset, at a dose of 300 mg nirmatrelvir/100 mg ritonavir twice daily for 5 days. 1

Indications

Paxlovid is indicated for treating mild-to-moderate COVID-19 in adults at high risk for progression to severe disease, including hospitalization or death 1. The WHO guidelines stratify recommendations by risk level:

• High-risk patients: Strong conditional recommendation for use 2
• Moderate-risk patients: Conditional recommendation for use 2
• Low-risk patients: Conditional recommendation AGAINST use 2

Paxlovid is NOT approved for pre-exposure or post-exposure prophylaxis 1.

Risk Factors Defining High-Risk Patients

High-risk patients include those with:

• Age ≥65 years
• Immunocompromised status
• Chronic lung disease (excluding simple asthma/COPD)
• Diabetes mellitus with complications
• Cardiovascular disease including myocardial infarction
• Unvaccinated status 2, 3

Dosing Regimen

Standard Dosing

300 mg nirmatrelvir (two 150 mg tablets) + 100 mg ritonavir (one 100 mg tablet) taken together orally every 12 hours for 5 days 2, 1

• Initiate as soon as possible after COVID-19 diagnosis and within 5 days of symptom onset 2, 1
• Can be taken with or without food 1
• Nirmatrelvir MUST be co-administered with ritonavir 1

Dose Adjustments for Renal Impairment

Moderate renal impairment (eGFR 30-59 mL/min):

• Reduce to 150 mg nirmatrelvir (one 150 mg tablet) + 100 mg ritonavir (one 100 mg tablet) twice daily for 5 days 2, 1

Severe renal impairment (eGFR <30 mL/min):

• NOT recommended in the FDA label 1
• However, recent evidence suggests that 150 mg nirmatrelvir/100 mg ritonavir once daily may be safe and effective in severe renal impairment, including patients on hemodialysis 4

Hepatic Impairment

Severe hepatic impairment (Child-Pugh Class C): NOT recommended 1

Contraindications

Absolute Contraindications

1. Clinically significant hypersensitivity to nirmatrelvir or ritonavir 1

2. Co-administration with drugs highly dependent on CYP3A for clearance where elevated concentrations cause serious/life-threatening reactions 1

3. Co-administration with potent CYP3A inducers that significantly reduce nirmatrelvir/ritonavir levels, risking loss of virologic response 1

Critical Drug-Drug Interactions

Ritonavir is a potent CYP3A4 inhibitor causing extensive drug-drug interactions 2, 1. This is the most significant limitation to Paxlovid use.

Before prescribing:

1. Review ALL patient medications for CYP3A interactions
2. Determine if comedications require dose adjustment, temporary discontinuation, or additional monitoring
3. Use the Liverpool COVID-19 Drug Interaction Tool for comprehensive interaction checking 2

Common problematic interactions include:

• Certain statins
• Immunosuppressants
• Anticoagulants
• Antiarrhythmics
• Sedatives/anxiolytics
• Some anticonvulsants 5

Management options are limited to:

• Temporarily pausing the comedication during the 5-day course
• Counseling patients on additional risks
• Choosing alternative COVID-19 therapy if interactions cannot be safely managed 5

Efficacy and Safety

Benefits

In unvaccinated, high-risk patients treated within 5 days of symptom onset 6, 7:

• 89% relative risk reduction in hospitalization or death (0.77% vs 7.01% in placebo; absolute risk reduction 6.32%) 6, 7
• All 13 deaths occurred in the placebo group (0% vs 1.8% mortality) 6, 7
• Significant viral load reduction at day 5 6
• Real-world data confirms 39% reduction in hospitalization risk and 61% reduction in death 8

Paxlovid is superior to molnupiravir (greater hospitalization reduction, no mutagenesis concerns) and superior to remdesivir (oral vs IV administration) when drug interactions can be managed 2.

Adverse Effects

• Most common: Dysgeusia (altered taste, 5.6%) and diarrhea (3.1%) 1, 6
• Serious adverse events: Lower than placebo (1.6% vs 6.6%) 6
• Discontinuation due to adverse events: Lower than placebo (2.1% vs 4.2%) 6
• Hypersensitivity reactions: Anaphylaxis, Stevens-Johnson syndrome, toxic epidermal necrolysis reported 1
• Hepatotoxicity: Transaminase elevations, clinical hepatitis possible 1

Special Populations

Pregnancy/Breastfeeding:

• Can be considered as an option despite uncertainty regarding serious adverse reactions
• No reports of adverse reactions in WHO Vigibase to date 2

HIV-1 infection:

• Risk of developing HIV protease inhibitor resistance in uncontrolled/undiagnosed HIV-1 infection 1

Vaccinated patients:

• Absolute risk reduction for hospitalization similar to unvaccinated patients
• Particularly beneficial in patients ≥65 years 8

Common Pitfalls

1. Missing the 5-day treatment window - Efficacy depends on early initiation
2. Failing to check drug interactions - Can lead to serious adverse events or treatment failure
3. Prescribing to low-risk patients - No meaningful benefit, wastes resources
4. Incorrect dosing in renal impairment - Risk of drug accumulation
5. Using as prophylaxis - Not indicated and not effective for this purpose 1

Equity Considerations

Disparities exist in Paxlovid access and prescription rates, with lower treatment rates among Black and Hispanic/Latino patients and those in socially vulnerable communities 8. When supplies are limited, prioritize patients at highest risk for severe outcomes 2.